Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Segment Reporting Information [Line Items]
Revenues:		$ 13,283	$ 13,007	$ 28,162	$ 31,492
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1]	(103)	2,269	3,318	8,539
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Revenues:	[2]	292	317	567	630
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1],[2]	(1,985)	(910)	(3,992)	(2,225)
Reconciling Items [Member] | Amortization of Intangible Assets [Member]
Segment Reporting Information [Line Items]
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1]	(1,307)	(1,184)	(2,615)	(2,287)
Reconciling Items [Member] | Acquisition-Related Items [Member]
Segment Reporting Information [Line Items]
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1]	(617)	(387)	(1,125)	(550)
Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1],[3]	(2,091)	(293)	(2,469)	(958)
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues:		12,991	12,690	27,595	30,863
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues:	[4]	12,991	12,690	27,595	30,863
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1],[4]	$ 5,897	$ 5,042	$ 13,519	$ 14,559

[1] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations and overhead costs associated with our manufacturing operations are now included in Biopharma’s earnings. We have reclassified $2.0 billion and $3.4 billion of net costs in the second quarter and first six months of 2023, respectively, from Other business activities to Biopharma to conform to the current period presentation.

[2] Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.

[3] Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the second quarter and first six months of 2024 includes, among other items, restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.2 billion (primarily recorded in Restructuring charges and certain acquisition-related costs). See Note 3.

[4] Biopharma’s revenues and earnings in the first six months of 2024 reflect a non-cash favorable product return adjustment of $771 million recorded in the first quarter of 2024 (see Note 13C). Biopharma’s earnings also include dividend income from our investment in ViiV of $74 million in the second quarter of 2024 and $91 million in the second quarter of 2023, and $135 million in the first six months of 2024 and $183 million in the first six months of 2023.